Infectious Diseases
|
New Approaches to Pediatric Skin and Skin Structure Infections |
New Approaches to Pediatric Skin and Skin Structure Infections | |||||||||
| Dear Colleague, |
|||||||||
| Uncomplicated bacterial skin and skin structure infections are among the most frequently seen infections in the community setting, and the vast majority of them are caused by Staphylococcus aureus and streptococcal species. The resistance of S. aureus to numerous antimicrobial agents demonstrates the amazing evolutionary ability of these organisms. Initially susceptible to penicillin G, the bacteria soon produced β-lactamases that inactivated both penicillins and aminopenicillins. This resistance mechanism was thwarted by the development of penicillinase-resistant penicillins, such as methicillin and oxacillin, but a different mechanism to resist these agents was quickly observed in the early 1960s. |
|||||||||
| Methicillin-resistant S. aureus (MRSA) became endemic in many hospitals in the 1980s, causing skin and surgical wound infections, pneumonia, and septicemia. In the late 1990s they began to infect previously healthy adults and children in the community, and now predominate in some areas of the United States and elsewhere. |
|||||||||
| The emergence of these strains has led to changes in our empiric treatment of skin infections, which is the focus of this Tx Reporter. We will outline the differences between community-acquired MRSA and hospital-acquired MRSA. What are the uses of topical treatment? And when should a child with a skin infection be hospitalized? |
|||||||||
| We are pleased to bring you this activity, which represents a distillation of a satellite symposium held in Atlanta in October, 2006. We hope you find it helpful and informative. |
|||||||||
| Sincerely, | |||||||||
|
|||||||||
| top |
|||||||||
TARGET AUDIENCE |
|||||||||
| This activity has been designed for pediatricians, dermatologists, and infectious disease specialists who treat patients with skin and skin structure infections. | |||||||||
ACTIVITY GOAL |
|||||||||
| The goal of this activity is to provide clinicians with the latest scientific and clinical information on the management of pediatric skin and skin structure infections. | |||||||||
LEARNING OBJECTIVES |
|||||||||
|
|||||||||
| top | |||||||||
CME INFORMATION |
|||||||||
Statement of Accreditation |
|||||||||
| Projects In Knowledge is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. | |||||||||
Credit Designation |
|||||||||
| Projects In Knowledge designates this educational activity for a maximum of 1.5 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity. | |||||||||
|
|||||||||
| top | |||||||||
DISCLOSURE INFORMATION |
|||||||||
| The Disclosure Policy of Projects In Knowledge requires that presenters comply with the Standards for Commercial Support. All faculty are required to disclose any personal interest or relationship they or their spouse/partner have with the supporters of this activity or any commercial interest that is discussed in their presentation. Any discussions of unlabeled/unapproved uses of drugs or devices will also be disclosed in the course materials. | |||||||||
For complete prescribing information on the products discussed during this CME/CE activity, please see your current Physicians' Desk Reference (PDR). |
|||||||||
Ronald N. Jones, MD, has received grant/research support from AB BIODISK, Abbott Laboratories, AlamX, Arpida, AstraZeneca Pharmaceuticals LP, Avexa, Basilea Pharmaceuticals, Bayer Pharmaceuticals, Becton Dickinson, BioMerieux, Bristol-Myers Squibb, Cadence Pharmaceuticals, Cerexa, Chiron Corporation, Cognigen, Cubist Pharmaceuticals, Daiichi, Elan Pharmaceuticals, Elanco, Enanta, GlaxoSmithKline, Intrabiotics, Johnson & Johnson, LG Chemicals, Merck & Co, Inc, Micrologix, Novartis Pharmaceuticals Corporation, Optimer, Ordway, Oscient Pharmaceuticals, Osmotics, Peninsula, Pfizer Inc, Replidyne, Inc, Schering-Plough Corporation, Sequoia, Serenex, Shionogi, Theravance, TREK Diagnostic Systems, Vicuron Pharmaceuticals, and Wyeth Pharmaceuticals. |
|||||||||
Dennis L. Stevens, MD, has received grant/research support from Arpida, Cubist Pharmaceuticals, Pfizer Inc, and Wyeth Pharmaceuticals. |
|||||||||
Peer Reviewer has no significant relationships to disclose. |
|||||||||
Projects In Knowledge's staff members have no significant relationships to disclose. |
|||||||||
This Tx Reporter will include a discussion of retapamulin, an investigational agent with an FDA approvable letter, as well as the unlabeled uses of FDA-approved drugs including trimethoprim-sulfamethoxazole (TMP-SMX) and mupirocin. |
|||||||||
Conflicts of interest are thoroughly vetted by the Executive Committee of Projects In Knowledge. All conflicts are resolved prior to the beginning of the activity by the Trust In Knowledge peer review process. |
|||||||||
The opinions expressed in this activity are those of the faculty and do not necessarily reflect those of Projects In Knowledge. |
|||||||||
This CME activity is provided by Projects In Knowledge solely as an educational service. Specific patient care decisions are the responsibility of the clinician caring for the patient. |
|||||||||
This independent CME activity is supported by an educational grant from GlaxoSmithKline. | |||||||||
| top
1785 |
|||||||||
|
|
|||||||||
